0
0.5
1
1.5
2+
Mortality
-11%
Improvement
Relative Risk
c19 early.org/u
Yang et al. Budesonide for COVID-19 LATE TREATMENT
Favors budesonide
Favors control
The relationship between oxygen therapy, drug therapy, and COVID-19 mortality
Yang et al. ,
The relationship between oxygen therapy, drug therapy, and COVID-19 mortality ,
Open Medicine, doi:10.1515/med-2022-0569
Retrospective 185 hospitalized COVID-19 patients in China, showing no significant difference in mortality with budesonide use in unadjusted results.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
risk of death, 10.8% higher , RR 1.11, p = 0.85 , treatment 30 of 125 (24.0%), control 13 of 60 (21.7%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yang et al., 31 Aug 2022, retrospective, China, peer-reviewed, median age 62.0, 12 authors, study period 1 January, 2020 - 29 February, 2020.
Contact:
2205603@tongji.edu.cn, 1220775601@qq.com, 29553185@qq.com.
Abstract: Open Medicine 2022; 17: 1833–1839
Research Article
Ling Yang*#, Guoxi Chen#, Yuyang Cai#, Ye An#, Xiaopan Li#, Ying Chen, Cheng Xu, Chen Ji,
Xing Lan, Yaling Wang, Hai Huang*, Li Han*
The relationship between oxygen therapy, drug
therapy, and COVID-19 mortality
https://doi.org/10.1515/med-2022-0569
received March 17, 2022; accepted August 24, 2022
Abstract: Since December, 2019, Wuhan, China, has
experienced an outbreak of coronavirus disease 2019
(COVID-19). We conducted a retrospective study of COVID-19
inpatients in Wuhan Pulmonary Hospital (Wuhan, China)
from January 1 to February 29, 2020. The subjects were
divided into four groups due to different treatment
regimes. We used the Kaplan–Meier method to determine the cumulative rates of in-hospital death and the
Cox proportional hazard model to calculate the risk factors and corresponding hazard ratios. A total of 185
patients were included in this study. The median age
of the patients was 62 years, including 94 men and 91
women. Kaplan–Meier analysis demonstrated that mortality was higher in older patients, higher in men, and
lower in the low-flow oxygen therapy group. Body mass
# Ling Yang, Guoxi Chen, Yuyang Cai, Ye An, Xiaopan Li contributed equally to this work.
* Corresponding author: Ling Yang, Department of Geriatrics,
Shanghai Fourth People’s Hospital Affiliated to Tongji University,
Shanghai, China, e-mail: 2205603@tongji.edu.cn
* Corresponding author: Hai Huang, Tuberculosis department,
Wuhan Pulmonary Hospital, Wuhan, China,
e-mail: 1220775601@qq.com
* Corresponding author: Li Han, Department of Geriatrics, Shanghai
Jiaotong University School of Medicine Xinhua Hospital, Shanghai,
China, e-mail: 29553185@qq.com
Guoxi Chen, Xing Lan, Yaling Wang: Tuberculosis department,
Wuhan Pulmonary Hospital, Wuhan, China
Yuyang Cai: School of Public Health, Shanghai Jiaotong University
School of Medicine, Shanghai, China
Ye An, Ying Chen, Cheng Xu: Department of Geriatrics, Shanghai
Jiaotong University School of Medicine, Xinhua Hospital, Shanghai,
China
Xiaopan Li: Pudong Institute of Preventive Medicine, Fudan
University, Shanghai, China
Chen Ji: Warwick Clinical Trials Unit, Warwick Medical School,
Warwick, Great Britain
Open Access. © 2022 the author(s), published by De Gruyter.
License.
index (BMI) had no influence on mortality, as well as
high flow oxygen therapy, Lopinavir–ritonavir (LPV/r)
therapy, and the interferon-alpha add LPV/r therapy. Cox
proportional hazard regression confirmed that the low
flow oxygen therapy was independent protective factor
for in-hospital death after adjusting for age, gender, and
BMI. In conclusion, the mortality was higher in older
patients, higher in men, and lower in the low-flow oxygen
therapy group. BMI had no influence on mortality, as well
as high flow oxygen therapy, LPV/r therapy, and interferon-alpha add LPV/r therapy.
Keywords: drugs treatment, COVID-19, pneumonia, mortality
Late treatment is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit